Brexucabtagene autoleucel
- Generic Name
- Brexucabtagene autoleucel
- Brand Names
- Tecartus
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 4MD2J2T8SJ
- Background
Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib and acalabrutinib, the prognosis for MCL patients remains poor and those that relapse following B...
- Indication
Brexucabtagene autoleucel is a modified autologous chimeric antigen receptor (CAR) T cell immunotherapy indicated for the treatment of relapsed or refractory mantle cell lymphoma (MCL) in adult patients. It is additionally indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
...
- Associated Conditions
- Refractory Mantle Cell Lymphoma, Relapsed Mantle Cell Lymphoma, Refractory B-cell precursor acute lymphoblastic leukemia, Relapsed B cell precursor Acute lymphoblastic leukemia
- Associated Therapies
- -
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
- Conditions
- Interventions
- First Posted Date
- 2024-08-14
- Last Posted Date
- 2024-08-14
- Target Recruit Count
- 60
- Registration Number
- NCT06553872
- Locations
- 🇺🇸
Univ of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Stanford Cancer Center, Stanford, California, United States
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
- First Posted Date
- 2023-03-20
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Kite, A Gilead Company
- Registration Number
- NCT05776134
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
- First Posted Date
- 2021-09-13
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 700
- Registration Number
- NCT05041309
- Locations
- 🇯🇵
Kyoto University Hospital, Kyoto, Japan
🇯🇵Okayama University Hospital, Okayama, Japan
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)
- Conditions
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Kite, A Gilead Company
- Target Recruit Count
- 125
- Registration Number
- NCT02614066
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of MD Greenbaum Comprehensive Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.